Weight loss jabs could almost halve risk of obesity-related cancers beyond slimming down, study suggests
Weight loss injections could help prevent cancer beyond helping people slim down, new research suggests.
The study said that there were similar rates of obesity-related cancer among patients treated with the injections and those given weight loss, or bariatric, surgery.
It also found weight loss jabs, officially GLP-1 receptor agonists, could almost halve the risk of related - in addition to the expected health benefits from losing weight.
Dr Yael Wolff Sagy, the study's co-lead author from Clalit Health Services in Tel-Aviv, Israel, said a "direct effect" of the injections was that they were found "to be 41% more effective at preventing obesity-related cancer".
She added: "We do not yet fully understand how GLP-1s work, but this study adds to the growing evidence showing that weight loss alone cannot completely account for the metabolic, anti-cancer, and many other benefits that these medications provide."
Being overweight or obese is the second biggest cause of cancer in the UK, causing more than one in 20 cancer cases, according to the NHS.
Read more:
In the study, researchers looked at electronic health record data for obese people and those with type 2 diabetes, all with no prior history of cancer, who were treated with first-generation GLP-1 receptor agonists.
Over a typical follow-up of seven and a half years, 298 patients were diagnosed with obesity-related cancer, with the most common types being breast, bowel and womb cancer.
The analysis found that obesity-related cancer occurred in 150 of 3,178 bariatric surgery patients and in 148 of 3,178 patients taking GLP-1 receptor agonists, despite the "relative advantage" of bariatric surgery in weight reduction.
Further study suggested the drugs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41% lower relative risk compared to bariatric surgery.
Co-lead Professor Dror Dicker, from Hasharon Hospital, Rabin Medical Centre in Israel, suggested the protective effects of the drugs "likely arise from multiple mechanisms, including reducing inflammation".
"New generation, highly potent GLP1-RAs with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers," he added, before warning that future research is needed "to make sure that these drugs do not increase the risk for non-obesity-related cancers".
Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, also cautioned that the study "cannot confirm or refute any links of incretin-based therapies [medicines to treat type 2 diabetes] with cancer as the design was not a trial but rather observational".
Read more from Sky News:
The study was published in the journal eClinicalMedicine, and was presented at the European Congress on Obesity in Malaga.
It comes as the NHS weighs up offering weight loss drugs from pharmacies at the cost of a standard prescription - £9.90.
At the moment, there is a two-year waiting list for Wegovy on the NHS - and last year, showed the rollout is happening far more slowly than planned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Urgent call for south London blood donors amid 'slump' after bank holidays
NHS Blood and Transplant is asking South Londoners to help fill a donation shortfall caused by recent bank holidays. There are hundreds of appointments available at Brixton Donor Centre, with 1,000 slots needing to be filled each week to meet demand. The high number of bank holidays, combined with the start of the half-term break, has increased pressure on blood stocks. The NHS is particularly keen to see new and lapsed donors return. Brixton Donor Centre welcomes life-saving donors to South London (Image: NHS) Gerry Gogarty, director of blood supply at NHS Blood and Transplant, said: "The need for blood never stops. "We are extremely grateful to everyone who has donated so far this year, but we must act now to avoid falling behind. "To avoid facing a 'spring slump' in donations, we urgently need donors to book an appointment today – and help us fill appointments over the weeks ahead. "If you can't find an appointment straightaway, please book further ahead or keep checking back to help fill last-minute availability or cancellations. "Each donation has the power to save up to three lives." There is a particular need for donors of black heritage to meet the growing need for blood to treat sickle cell, the country's fastest-growing inherited blood disorder, which predominantly affects black communities. Black heritage donors are 10 times more likely than the white population to have the specific Ro blood type used to treat sickle cell patients. Around 1,300 black donors a month are needed to provide life-saving transfusions to sickle cell patients, as well as for use in emergencies, childbirth, during surgery, cancer treatments, and other medical conditions. Brixton Donor Centre, which opened in December 2024, has had 7 per cent of all donations with the in-demand Ro subtype, compared with 2 per cent nationally. South Londoners with O negative, O positive and A positive blood types are also being encouraged to donate, as these blood groups are in high demand. Brixton Blood Donor Centre manager Rexford Osei-Bonsu said: "I'm immensely proud of the thousands of people who have given blood in Brixton, but the holidays have meant that we need more people to come forward. "Giving blood is easy and painless and takes about an hour of your time to make a life-saving difference." Appointments can be made by calling 0300 123 2323 or visiting "We have the capacity to deliver more than 1,000 appointments a week and are happy to work round your availability, whether that's on your way to work, during your lunch break or as you head home."
Yahoo
5 hours ago
- Yahoo
Millions more to get test results via NHS app, government says
The NHS app will become the default method of communication for millions more patients in England and save the health service £200m over the next three years, the government has said. More test results, screening invitations and appointment reminders will be sent directly to smartphones as part of a £50m investment in the app, in a move away from traditional communication methods such as letters. It is estimated that at least 50 million letters are sent to patients each year. The Department of Health and Social Care said that people who cannot access app messaging - including elderly patients - will receive text messages and then a letter as a last resort, and NHS phone lines would be freed up. The department says 270 million messages will be sent through the NHS app this financial year - an increase of 70 million on the previous year. Push notifications will provide appointment reminders to patients to try to reduce the risk of no attendance - with around eight million missed appointments in elective care missed in 2023/24. Work is also under way to enable users of the app to add appointments to their phone calendars and request help from their local GP surgeries. Figures show that more than 11 million people in the UK log into the NHS app every month, while almost 20 million are opted in to receive healthcare messages from the app. It is hoped the changes will give patients better access to manage their healthcare journey and make informed decisions about their care. NHS app services, which were launched in December 2018, are now used in 87% of hospitals across England. Health Secretary Wes Streeting said further investment in the app would bring the NHS into the digital age so that being a patient was as "convenient as online banking or ordering a takeaway". He added that moving away from paper communication could free up funding for front line services. Rachel Power, chief executive of the Patient's Association, said the upgrade was a "significant step in modernising how patients receive information". The British Medical Association (BMA) has previously warned that a reliance on apps to the NHS to communicate with patients risked alienating patients who don't have access to digital technology. It followed the government's announcement in January that it planned to allow more patients in England to book treatments and appointments through the app. Last month, NHS England announced millions of patients would be able to get "Amazon-style" tracking updates on their prescriptions through the app, to check if their medicines are ready to collect or have been despatched for delivery. New app trial cuts skin cancer referrals by 50% NHS App upgrade to give patients more choice over treatment Patients to get full access to record on NHS App
New York Post
6 hours ago
- New York Post
Weight loss drugs like Ozempic could mess with your birth control — and get you pregnant
A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the medications. The warning comes as women flood social media with stories of their so-called 'Ozempic babies' — including surprise pregnancies while on the pill. Trying to shed pounds, not grow a baby bump? Here's what you need to know about GLP-1s, pregnancy and the best contraception options to stay protected. 4 Studies show that at least one in eight US adults have tried GLP-1s. íÅí°íâ¬í¸í½í° íâíµí¼íµíËí°í¾ – What's in your GLP-1? Several GLP-1 drugs dominate the market, including Ozempic and Wegovy. Both contain semaglutide, an active ingredient that mimics a natural hormone in the body that boosts insulin production, slows digestion and curbs appetite. Then there's Saxenda and Victoza, powered by liraglutide, which functions in a similar way. Newer drugs like Mounjaro and Zepbound rely on tirzepatide, a key ingredient that targets a second hormone involved in appetite and blood sugar control. A surprise side effect While gastrointestinal symptoms like nausea, vomiting and diarrhea are common with GLP-1s, the surprise side effect making waves is unexpected pregnancy. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has received 28 reports related to pregnancy in patients on tirzepatide, and nine each for semaglutide and liraglutide. 4 Women on tirzepatide-based GLP-1s should use barrier contraception. nenetus – In an alert this week, the agency warned that tirzepatide may reduce the effectiveness of oral contraceptives, especially in women with higher body weight. As a result, it recommended using barrier methods like condoms while on drugs like Mounjaro. So far, there's no evidence that GLP-1s affect non-oral birth control like IUDs, implants, patches, or rings, according to the UK's Faculty of Reproductive Healthcare. And yes, the advice applies even to women previously told they were infertile. GLP-1s have been shown to boost fertility by aiding weight loss, reducing inflammation and improving insulin sensitivity — leading some to conceive just months after starting treatment. 4 GLP-1 agonists can increase your fertility, but they can also interfere with pregnancy. Louis-Photo – Can you take GLP-1s while pregnant? Experts say no — at least not yet. There's not enough data to confirm whether GLP-1s are safe during pregnancy. While a some human studies suggests there is no harm in first-trimester use, testing in animals has shown the drugs could increase the risk of miscarriage and birth defects. 4 Scientists are still working to understand whether GLP-1s can negatively impact a developing fetus. Evrymmnt – Another reason to skip GLP-1s while pregnant: they suppress your appetite and can trigger gastrointestinal issues, which may lead to nutrient deficiencies that impact fetal development. The drugs should also be avoided during breastfeeding, since there's not enough research to confirm safety for infants. Trying to conceive? Here's the timeline If you're planning to get pregnant, the MHRA recommended stopping GLP-1s before you start trying to conceive and giving your body time to clear the drugs. For semaglutide users, that means quitting at least two months ahead. If you're on tirzepatide, stop one month before trying. Liraglutide clears the system faster, so you can stop right before you start trying to conceive.
